Patents by Inventor Norbert Schmees

Norbert Schmees has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200289509
    Abstract: The present invention covers 2-hetarylpyrimidine-4-carboxamide compounds of general formula (I): in which X, Y, Z, R1, R2 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 16, 2017
    Publication date: September 17, 2020
    Applicants: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Julien LEFRANC, Norbert SCHMEES, Ulrike RÖHN, Ludwig ZORN, Judith GÜNTHER, Ilona GUTCHER, Lars RÖSE, Benjamin BADER, Detlef STÖCKIGT, Michael PLATTEN
  • Publication number: 20200283395
    Abstract: The present invention covers 2-phenylpyrimidine-4-carboxamide compounds of general formula (I): (I) 5 in which X, Y, Z, R1, R2, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 16, 2018
    Publication date: September 10, 2020
    Inventors: Julien LEFRANC, Norbert SCHMEES, Ulrike RÖHN, Ludwig ZORN, Judith GÜNTHER, Ilona GUTCHER, Lars RÖSE, Benjamin BADER, Detlef STÖCKIGT, Michael PLATTEN
  • Publication number: 20200246347
    Abstract: Protein-inhibitory substituted pyrrolopyridine derivatives of formula (I) in which X, Y, R1, R2, R3 and R4 are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: June 7, 2018
    Publication date: August 6, 2020
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
    Inventors: Norbert SCHMEES, Bernd BUCHMANN, Anders Roland FRIBERG, Hans BRIEM, Manfred HUSEMANN, Ulf BOMER, Gabriele LEDER, Rafael CARRETERO, Detlef STOCKIGT, Rienk OFFRINGA
  • Publication number: 20200237757
    Abstract: The present invention covers 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: May 23, 2017
    Publication date: July 30, 2020
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ)
    Inventors: Norbert SCHMEES, Ilona GUTCHER, Horst IRLBACHER, Benjamin BADER, Na ZHAO, Michael PLATTEN, Ulrike ROEHN, Ludwig ZORN, Lars ROESE, Detlef STOECKIGT
  • Publication number: 20200199083
    Abstract: The present invention covers 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamide compounds of general formula (I): in which R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5 and X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 9, 2018
    Publication date: June 25, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Jörg WEISKE, Carlo STRESEMANN, Stefan Nikolaus GRADL, Ulrike RÖHN, Clara CHRIST, Holger STEUBER, Manfred HUSEMANN, Norbert SCHMEES, Kai THEDE, Stephan SIEGEL, Antonius TER LAAK
  • Patent number: 9890147
    Abstract: What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R1a, R1b, R1c, R2, R3, R4, R5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumor disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: February 13, 2018
    Assignee: Bayer Pharma Aktiengesellshaft
    Inventors: Stephan Siegel, Stefan Bäurle, Arwed Cleve, Bernard Haendler, Amaury Ernesto Fernandez-Montalvan, Ursula Mönning, Sabine Krause, Pascale Lejeune, Norbert Schmees, Matthias Busemann, Simon Holton, Joachim Kuhnke
  • Patent number: 9663523
    Abstract: The present invention relates to BET-protein-inhibitory, in particular BRD4-inhibitory 5-aryltriazoloazepines of the general formula (I) in which R1, R2, R3 and R4 have the meanings given for the general formula (I), to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for neoplastic disorders. The present invention further relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammatory diseases, in atherosclerotic disorders and in male fertility control.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: May 30, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Norbert Schmees, Joachim Kuhnke, Bernard Haendler, Roland Neuhaus, Pascale Lejeune, Stephan Siegel, Martin Krüger, Amaury Ernesto Fernandez-Montalvan, Hermann Künzer, Daniel Gallenkamp
  • Publication number: 20170121322
    Abstract: The present invention relates to BET protein-inhibitory, especially BRD4-inhibitory 3,4-dihydropyrido[2,3-b]pyrazinones with a meta-substituted aromatic amino or ether group of the general formula (I) in which A, X, Y, R1, R2, R3, R4, R5, R6 and n are each as defined in the description, to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of tumour disorders. Furthermore, this invention relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammatory diseases, in atherosclerotic disorders and in male fertility control.
    Type: Application
    Filed: June 15, 2015
    Publication date: May 4, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Norbert SCHMEES, Bernard HAENDLER, Detlef STÖCKIGT, Richard Alexander BISSELL, Richard Alexander BOUGLAS, Ian STEFANUTI, Stephan SIEGEL
  • Publication number: 20160272635
    Abstract: The present invention relates to substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of BET proteins, in particular BRD4 proteins, and Polo-like kinases, in particular Plk-1 proteins of the general formula (I) in which A, X, R1, R2, R3, R4, R5, R6, R7 and n are each as defined in the description, to intermediates for preparation of the compounds according to the invention, to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of tumour disorders. Furthermore, the present invention relates to the use of the dihydropyrido[3,4-b]pyrazinones according to the invention in viral infections, in neurodegenerative disorders, in inflammation disorders, in atherosclerotic disorders and in male fertility control.
    Type: Application
    Filed: July 21, 2014
    Publication date: September 22, 2016
    Inventors: Norbert Schmees, Benjamin Bader, Bernard Haendler, Volker Schulze, Ingo Hartung, Niels Bohnke, Florian Puehler
  • Publication number: 20160262923
    Abstract: The present invention relates to an improved method of contraception which addresses the problems of initial bleeding and spotting associated with the use of intrauterine delivery systems, and to an improved intrauterine delivery system.
    Type: Application
    Filed: October 14, 2014
    Publication date: September 15, 2016
    Applicant: Bayer Oy
    Inventors: Manja AHOLA, Christine TALLING, Bernhard LINDENTHAL, Ulrike FUHRMANN, Lüder M. FELS, Katja PRELLE, Norbert SCHMEES
  • Publication number: 20160193206
    Abstract: The present invention relates to BET protein-inhibitory, especially BRD4-inhibitory, dihydropyridopyrazinones of the general formula (I) in which A, X, R1, R2, R3, R4, R4, R6, R7 and n have the meanings given in the description, to intermediates for preparation of the compounds according to the invention, to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of neoplastic disorders. This invention further relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammation diseases, in atherosclerotic disorders and in male fertility control.
    Type: Application
    Filed: December 17, 2013
    Publication date: July 7, 2016
    Inventors: Norbert SCHMEES, Benjamin BADER, Bernard HAENDLER, Detlef STÖCKIGT, Pascale LEJEUNE, Amaury Ernesto FERNANDEZ-MONTALVAN, Timo STELLFELD, Daniel GALLENKAMP
  • Publication number: 20160176867
    Abstract: The present invention relates to BET protein-inhibitory, especially BRD4-inhibitory, dihydroquinoxalinones and dihydropyridopyrazinones of the general formula (I) in which A, X, R1, R2, R3, R4, R5, R6 and n are each as defined in the description, to intermediates for preparation of the inventive compounds, to pharmaceutical compositions comprising the inventive compounds, and to the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of neoplastic disorders. This invention further relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammation diseases, in atherosclerotic disorders and in male fertility control.
    Type: Application
    Filed: July 7, 2014
    Publication date: June 23, 2016
    Inventors: Norbert SCHMEES, Bernard HAENDLER, Detlef STÖCKIGT, Daniel GALLENKAMP, Richard BISSELL, Richard Alexander BOUGLAS
  • Publication number: 20160009725
    Abstract: What is described are BET protein-inhibitory, especially BRD2-, BRD3- and BRD4-inhibitory, bicyclo- and spino-substituted pyrrolo- and pyrazolodiazepines of the general formula I in which X, Y, n, m, R1, R2, R3, R4 and R5 are each as defined in the description, to intermediates for preparation of the inventive compounds, to pharmaceutical compositions comprising the inventive compounds, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for tumour disorders. Also described is the use of the compounds according to the invention as BET protein inhibitors for benign hyperplasias, for atherosclerotic disorders, for sepsis, for autoimmune disorders, for vascular disorders, for viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for male fertility control.
    Type: Application
    Filed: February 17, 2014
    Publication date: January 14, 2016
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Norbert SCHMEES, Bernd BUCHMANN, Bernard HAENDLER, Roland NEUHAUS, Pascale LEJEUNE, Martin KRÜGER, Amaury Ernesto FERNANDEZ-MONTALVAN, Hermann KÜNZER
  • Publication number: 20150376196
    Abstract: BET protein-inhibitory, especially BRD2-, BRD3- and BRD4-inhibitory, 4-substituted pyrrolo- and pyrazolodiazepines of the general formula I are described, in which X, Y, n, m, p, R1, R2, R3, R4 and R5 are each as defined in the description, as are pharmaceutical compositions comprising the inventive compounds, and the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of neoplastic disorders. Also described is the use of the inventive compounds as BET protein inhibitors in benign hyperplasias, in atherosclerotic disorders, in sepsis, in autoimmune disorders, in vascular disorders, in viral infections, in neurodegenerative disorders, in inflammatory disorders and in male fertility control.
    Type: Application
    Filed: February 18, 2014
    Publication date: December 31, 2015
    Inventors: Norbert SCHMEES, Bernd BUCHMANN, Bernard HAENDLER, Roland NEUHAUS, Pascale LEJEUNE, Martin KRÜGER, Amaury Ernesto FERNANDEZ-MONTALVAN, Hermann KÜNZER, Hartmut REHWINKEL
  • Publication number: 20150344444
    Abstract: The present invention relates to BET protein-inhibitory, especially BRD4-inhibitory, dihydroquinoxalinones of the general formula (I) in which A, X, R1, R2, R3, R4, R5, R6, R7 and n are each as defined in the description, to intermediates for preparation of the inventive compounds, to pharmaceutical compositions comprising the inventive compounds, and to the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of neoplastic disorders. This invention further relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammation disorders, in atherosclerotic disorders and in male fertility control.
    Type: Application
    Filed: December 17, 2013
    Publication date: December 3, 2015
    Inventors: Norbert SCHMEES, Bernard HAENDLER, Detlef STÖCKIGT, Daniel GALLENKAMP
  • Publication number: 20150299201
    Abstract: The present invention relates to BET-protein-inhibitory, in particular BRD4-inhibitory 5-aryltriazoloazepines of the general formula (I) in which R1, R2, R3 and R4 have the meanings given for the general formula (I), to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for neoplastic disorders. The present invention further relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammatory diseases, in atherosclerotic disorders and in male fertility control.
    Type: Application
    Filed: September 25, 2013
    Publication date: October 22, 2015
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Norbert Schmees, Joachim Kuhnke, Bernard Haendler, Roland Neuhaus, Pascale Lejeune, Stephan Siegel, Martin Krüger, Amaury Ernesto Fernandez-Montalvan, Hermann Künzer, Daniel Gallenkamp
  • Publication number: 20150203483
    Abstract: What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R1a, R1b, R1c, R2, R3, R4, R5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumour disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.
    Type: Application
    Filed: August 13, 2013
    Publication date: July 23, 2015
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Stephan Siegel, Stefan Bäurle, Arwed Cleve, Bernard Haendler, Amaury Ernesto Fernandiez-Montalvan, Ursula Mönning, Sabine Krause, Pascale Lejeune, Norbert Schmees, Matthias Busemann, Simon Holton, Joachim Kuhnke
  • Publication number: 20150119372
    Abstract: The present invention describes intrauterine use of 18-methyl-15?,16?-methylene-19-nor-20-spirox-4-en-3-ones of the general formula (1) wherein R6 and R7 are hydrogen or a methylene group, in the treatment of menorrhagia, of uterine haemorrhages in general, and an intrauterine system for said use, comprising a compound of formula 1.
    Type: Application
    Filed: April 19, 2013
    Publication date: April 30, 2015
    Inventors: Norbert Schmees, Lars Röse, Tuula Valo, Katja Prelle, Reinhard Nubbemeyer, Henriikka Korolainen, Harri Jukarainen
  • Publication number: 20150065472
    Abstract: The present invention describes intrauterine use of 18-methyl-15?,16?-methylene-19-nor-20-spirox-4-en-3-ones of the general formula (1) in contraception and gynaecological treatment, and an intrauterine system comprising compounds of formula 1.
    Type: Application
    Filed: April 19, 2013
    Publication date: March 5, 2015
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Norbert Schmees, Lars Röse, Tuula Valo, Katja Prelle, Reinhard Nubbemeyer, Henriikka Korolainen, Harri Jukarainen
  • Publication number: 20140213575
    Abstract: The invention relates to 6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines, in particular for therapeutic purposes, pharmaceutical agents and use thereof in therapy, in particular for the prevention and treatment of tumour diseases.
    Type: Application
    Filed: August 27, 2012
    Publication date: July 31, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Norbert Schmees, Joachim Kuhnke, Bernard Haendler, Philip Lienau, Amaury Ernesto Fernandez-Montalvan, Pascale Lejeune, Stephan Siegel, William Scott